Trial · NCT02138253
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score | IDN-6556 | 25 | participants | ||
| Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score | Placebo | 14 | participants | ||
| Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score (Observed Cases Only) | IDN-6556 | 25 | Participants | ||
| Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score (Observed Cases Only) | Placebo | 14 | Participants | ||
| Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score | IDN-6556 | 27 | Participants | ||
| Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score | Placebo | 17 | Participants | ||
| Alanine Aminotransferase (ALT) - Change From Baseline | IDN-6556 | -3.7 | Standard Deviation 10 | U/L | |
| Alanine Aminotransferase (ALT) - Change From Baseline | Placebo | 43.7 | Standard Deviation 239.5 | U/L | |
| Aspartate Aminotransferase (AST) Change From Baseline | IDN-6556 | -4.0 | Standard Deviation 8.5 | U/L | |
| Aspartate Aminotransferase (AST) Change From Baseline | Placebo | 31.4 | Standard Deviation 161.8 | U/L | |
| Caspase 3/7 Change From Baseline | IDN-6556 | -296.1 | Standard Deviation 830.3 | Raw RLU | |
| Caspase 3/7 Change From Baseline | Placebo | 2081.2 | Standard Deviation 10116.4 | Raw RLU | |
| cCK18/M30 Change From Baseline | IDN-6556 | -104.7 | Standard Deviation 193.2 | U/L | |
| cCK18/M30 Change From Baseline | Placebo | -66.1 | Standard Deviation 176.9 | U/L | |
| flCK18/M65 Change From Baseline | IDN-6556 | -70.2 | Standard Deviation 189.0 | U/L | |
| flCK18/M65 Change From Baseline | Placebo | -98.6 | Standard Deviation 311.7 | U/L | |
| Ishak Modification of Knodell Histological Activity Index - Interface Hepatitis | IDN-6556 | Interface Hepatitis Score of 0 | 6 | Participants | |
| Ishak Modification of Knodell Histological Activity Index - Interface Hepatitis | Placebo | Interface Hepatitis Score of 0 | 5 | Participants | |
| Ishak Modification of Knodell Histological Activity Index - Interface Hepatitis | IDN-6556 | Interface Hepatitis Score of 1 | 14 | Participants | |
| Ishak Modification of Knodell Histological Activity Index - Interface Hepatitis | Placebo | Interface Hepatitis Score of 1 | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02138253/results